The Cardiovascular Genome

The most important conversation about your heart is the one your physician hasn’t had with your DNA.

A single sequencing of the human genome — once, for life — reveals the inherited foundations of cardiovascular risk that no blood test, no calcium scan, and no family history alone can read.

Human Longevity · Since 2013A reading

In the year 2000, a research consortium led by one scientist — Dr. J. Craig Venter — read the human genome for the first time. It cost three billion dollars and took thirteen years.

Today, the same sequencing can be done for the price of a good suit. What has not changed in twenty-five years is the genome itself. The 6.4 billion base pairs you carry today are the same 6.4 billion base pairs that were written into you at conception, and they will be the same on the day you die. Among them are the instructions that determine — to a degree that surprises most cardiologists — whether and when you will have a heart attack.

Approximately half of your lifetime cardiovascular risk is genetic. Polygenic risk scores derived from hundreds of thousands of sequenced genomes now predict coronary artery disease with greater accuracy than any cholesterol panel ever has. A single inherited variant in the PCSK9 gene can elevate your lifetime risk of heart attack twentyfold. The condition has a name — familial hypercholesterolemia — and it affects approximately one in two hundred and fifty adults. Ninety percent of them do not know they have it.

The annual physical, which measures three cholesterol numbers and a blood pressure reading, is incapable of telling you any of this. It is not designed to. It looks at the present. The genome describes the foundations.

This is what Human Longevity was built to read.

The Science of the Heart Genome

Three inheritances. One sequencing. A lifetime of clarity.

i.

The Monogenic

A single faulty gene — PCSK9, LDLR, APOB — can drive lifetime LDL elevation and inherited cardiomyopathies. Familial hypercholesterolemia is the most common monogenic disorder in medicine, and the most consistently missed.

ii.

The Polygenic

Cardiovascular risk is more often the additive consequence of thousands of small genetic effects. A polygenic risk score, calculated from your whole genome, predicts coronary artery disease with a precision unavailable from any single biomarker.

iii.

The Pharmacogenomic

How your body metabolizes statins, anticoagulants, and beta-blockers is determined by genes that vary substantially between individuals. The right drug at the right dose, prescribed the first time, is a function of reading them.

A Case · Recorded

His father died at fifty. His grandfather, at fifty.
Then his physician read his genome.

He was fifty-four. He called himself healthy. By every conventional measure, he was. His annual physical had been unremarkable for two decades.

Whole genome sequencing, performed in a single afternoon, identified an autosomal dominant variant in his PCSK9 gene — a clear marker for familial hypercholesterolemia, the same inherited condition that had ended his father’s life and his grandfather’s. A CT coronary calcium score, ordered the following week, confirmed early disease. An advanced lipid panel quantified it. Within a month, his cardiologist had prescribed a twice-yearly siRNA therapy specifically indicated for his variant.

He is now expected to live a normal lifespan.

Identifying details altered. Outcome representative; individual results vary.

What You Will Learn

Four readings of the heart, recorded once.

Each finding in your report is clinically formatted and physician-ready — designed to be handed to your cardiologist and acted upon.

i.

Your polygenic cardiovascular risk score

A single number, calibrated against hundreds of thousands of sequenced genomes, expressing your individual lifetime risk for coronary artery disease and heart attack — the most powerful predictor in cardiology that is not yet on most physicians' order forms.

ii.

Your inherited cholesterol disorders

Complete analysis of PCSK9, LDLR, and APOB — the three principal genes implicated in familial hypercholesterolemia. The condition affects an estimated one in two hundred and fifty adults. Nine in ten do not yet know they carry it.

iii.

Your hereditary rhythm and structural risks

Long QT syndrome. Hypertrophic cardiomyopathy. Brugada. Catecholaminergic polymorphic ventricular tachycardia. The conditions that, untreated, cause sudden cardiac death in otherwise healthy adults.

iv.

Your cardiovascular pharmacogenomics

How your genes influence your response to statins, anticoagulants, beta-blockers, and over two hundred additional medications — provided so that the right intervention can be prescribed at the right dose, the first time.

The Institution Behind the Reading

Human Longevity was founded in 2013 by the scientist who sequenced the first human genome. Its work has since been published in Nature Genetics, PNAS, and the American Journal of Human Genetics.

$600M
Invested in Research
75,000+
Genomes Sequenced
400M+
Variants Catalogued
Top 50
Nature Index Biomedical
Research and clinical partners

Mass General Brigham · Siemens Healthineers · Illumina · Buck Institute
Cleerly · Capital Group · J. Craig Venter Institute · CorTechs.ai · AMRA
Scientific Advisory Board includes Nobel laureates Geoffrey Hinton and Michael Levitt

What Arrives

One sequencing. One report. For life.

A clinical-grade whole genome sequencing in a CLIA-certified laboratory, returned as a physician-ready report — and re-analyzed each year as the science advances.

Cardiovascular Whole Genome Sequencing

$599
  • Whole genome sequencing — all 6.4 billion base pairs at 30× coverage
  • Polygenic cardiovascular risk score
  • Familial hypercholesterolemia analysis — PCSK9, LDLR, APOB
  • Hereditary arrhythmia and cardiomyopathy panel
  • Lp(a) genetic prediction
  • Pharmacogenomics for 200+ cardiovascular medications
  • Clinically formatted, physician-ready report
  • Annual re-analysis, included for life

One-time payment. No subscription. Saliva collection at home — no clinic visit, no blood draw. Eligible under HSA and FSA accounts in the United States. Processed in HLI’s CLIA-certified laboratory. Stored in HIPAA-compliant infrastructure. Same sequencing used in the $8,000 Executive Health Assessment.

A Reading, Requested

The genome you were born with is the most consequential conversation your physician has not yet had.

To begin, request your sequencing kit. The collection is performed at home. The report is delivered to you, and yours to share with the physician of your choosing.

Request Your Sequencing →

Or speak with a clinical specialist · 844-838-3322 · San Diego & San Francisco